Top

Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others)

Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 - 2020
Category : Diagnostic and Biotech  | Published Date : Dec-2013
enquire Customize Report GET DISCOUNT

Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. The global market for diagnostic biomarker is expected to reach about $30.6 billion in 2020, growing at CAGR of 16% from 2013 to 2020. Pharmaceutical companies, which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, and educational institutes. The companies are also increasing their investments in research and development.
Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However, application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.
The key players in this market that are profiled in the report include: Roche Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.), Epistem Ltd (U.K.), G.E. Healthcare Inc.(U.K).

KEY BENEFITS

  • Assessment and ranking the factors that favor the market growth and those factors which act as a hindrance for the growth of the market
  • The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011 and 2012
  • The report identifies and analyses top investment pockets and top winning strategies for diagnostic biomarker market
  • The report analyses the various strategies adopted by some of the key companies in the market
  • The report tracks and analyses key innovations and patents for biomarkers in the last five years

KEY MARKET SEGMENTS
DIAGNOSTIC BIOMARKER MARKET IS SEGMENTED AS FOLLOWS:
GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY TYPES

  • Biomarker of Exposure
  • Biomarkers of Diseases

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY APPLICATIONS

  • Risk Assessment
  • Development of Molecular Diagnostic
  • Disease Diagnosis
  • Drug Discovery and Development
  • Drug Formulation
  • Forensic Application
  • Others (DNA Fingerprinting and Others)

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY SERVICES

  • Sample Preparation
  • Assay Development
  • Biomarker Validation and Testing
  • Other Services

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • Row (Rest of World)

KEY AUDIENCES

  • Pharmaceutical companies
  • Government & Private research institutes
  • Academic institutes
  • Medical device manufacturing companies

CHAPTER 1 INTRODUCTION
 1.1 Scope and Coverage
 1.2 Report Description

CHAPTER 2 EXECUTIVE SUMMARY
 2.1 Biomarker Diagnosis Vs. Conventional Diagnosis
 2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?

CHAPTER 3 MARKET OVERVIEW
 3.1 Key Application of Diagnostic Biomarkers in Top Technologies
    3.1.1 Omics Technology
       3.1.1.1 Applications of Omics Technology
            3.1.1.1.1 Lung Disease Identification
            3.1.1.1.2 Quantifying Abnormalities
            3.1.1.1.3 Genetic Trait Diagnosis
            3.1.1.1.4 Analyzing Drug Efficiency
            3.1.1.1.5 Functional Food Development
            3.1.1.1.6 Pharmacogenomics
            3.1.1.1.7 Drivers
            3.1.1.1.8 Restraints
                   3.1.1.1.8.1 Lengthy Process
                   3.1.1.1.8.2 Ethical Problems
                   3.1.1.1.8.3 Sample Collection
                   3.1.1.1.8.4 Gene Expression
                   3.1.1.1.8.5 Inefficiency in Pre-Disease Identification
    3.1.2 Imaging Technology
       3.1.2.1 Application of Diagnostic Imaging Technology
       3.1.2.2 Drivers
            3.1.2.2.1 Faster Test Result
            3.1.2.2.2 Improved Nursing Services
            3.1.2.2.3 Noninvasive Technique
       3.1.2.3 Restraints
            3.1.2.3.1 Radiation Effect
            3.1.2.3.2 Complex Process
            3.1.2.3.3 Genetic Variation
       3.1.2.4 Trends
    3.1.3 Bioinformatics
       3.1.3.1 Applications of Bioinformatics
       3.1.3.2 Drivers
            3.1.3.2.1 Open Source of Information
            3.1.3.2.2 Relevant Information
            3.1.3.2.3 Forecasting of Information
       3.1.3.3 Restraints
            3.1.3.3.1 Difficulty in Practical Application
            3.1.3.3.2 Over-Fitting
            3.1.3.3.3 Complex Operation Process
            3.1.3.3.4 Security Issue
            3.1.3.3.5 Costly Management
            3.1.3.3.6 Virtual Storage
    3.1.4 Personalized Medicines
       3.1.4.1 Drivers
            3.1.4.1.1 Unique Solution
            3.1.4.1.2 Minimal Invasive
            3.1.4.1.3 Reduction in Failure
            3.1.4.1.4 Effective Prescription
       3.1.4.2 Restraints
            3.1.4.2.1 Need Specialized Setup for Treatment
            3.1.4.2.2 Liability Issue
            3.1.4.2.3 Ethical Question
    3.1.5 Others (Nutritional Technology)
 3.2 Importance of Non-Invasive Diagnostics
 3.3 Key Advantages of Dm
 3.4 Regulatory Scenario
 3.5 Reimbursement Issues
 3.6 Key Patents and Analysis
 3.7 Top Ten Factors Impacting DBM Market
    3.7.1 Non-Invasive Technique
    3.7.2 Drug Discovery and Development
    3.7.3 Cost Effective Tool for Diagnosis
    3.7.4 Multi-Marker Application
    3.7.5 Accuracy and Reliability
    3.7.6 Ethical Issues
    3.7.7 Gene Level Diagnosis
    3.7.8 Complex Processes
    3.7.9 Government Regulations
    3.7.10 Reimbursement Issues
 3.8 Top Investment Pockets
 3.9 Market Intelligence
    3.9.1 Top Three Winning Strategies
       3.9.1.1 Product Launch
       3.9.1.2 Collaboration and Agreement
       3.9.1.3 Merger and Acquisition
 3.10 Market Dynamics
    3.10.1 Drivers
        3.10.1.1 Cost Effective
        3.10.1.2 Non-Invasive
        3.10.1.3 Accuracy in Result
        3.10.1.4 Assistant in Clinical Trials
        3.10.1.5 Multi-Marker Application
        3.10.1.6 Gene Level Diagnosis
    3.10.2 Restrains
        3.10.2.1 Government Regulation
        3.10.2.2 Ethical Problems
        3.10.2.3 Conformation in Result
        3.10.2.4 Complex Process
    3.10.3 Opportunity
        3.10.3.1 Local Market
        3.10.3.2 Personalized Medicine
        3.10.3.3 Tissue Specific Treatment

CHAPTER 4 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY TYPES, 2013-2020, $MILLION
 4.1 Biomarker of Exposure
 4.2 Biomarkers of Disease

CHAPTER 5 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY APPLICATIONS, 2013-2020, $MILLION
 5.1 Risk Assessment
    5.1.1 Applications
       5.1.1.1 Oncology Treatment
       5.1.1.2 Cardiovascular Treatment
    5.1.2 Drivers
       5.1.2.1 Forecasting of Abnormal Conditions
       5.1.2.2 Cost Effective
    5.1.3 Restraints
       5.1.3.1 Government Regulations
       5.1.3.2 Ethical Issues
 5.2 Development of Molecular Diagnostic
    5.2.1 Application
       5.2.1.1 Prenatal Diagnostics
       5.2.1.2 Human Clinical Molecular Diagnostic Testing
       5.2.1.3 Veterinary Molecular Diagnostic Testing
       5.2.1.4 Identity Testing
       5.2.1.5 Histocompatibility Testing
    5.2.2 Drivers
       5.2.2.1 Uniformity in Test Result
       5.2.2.2 Cost Effective
       5.2.2.3 Fast Result
       5.2.2.4 More Profitable
       5.2.2.5 Automation
    5.2.3 Restraints
       5.2.3.1 Not Applicable for Twins Genomes
       5.2.3.2 Government Regulations
       5.2.3.3 Ethical Issues
 5.3 Disease Diagnosis
    5.3.1 Oncology
       5.3.1.1 Drivers
       5.3.1.2 Restraints
            5.3.1.2.1 Complex Process
            5.3.1.2.2 Conformation in Result
            5.3.1.2.3 Used for Early Diagnosis Only
    5.3.2 Cardiology
       5.3.2.1 Application
       5.3.2.2 Drivers
            5.3.2.2.1 Cost Effective
            5.3.2.2.2 Tissue Specific
            5.3.2.2.3 Accurate Result
       5.3.2.3 Restraints
            5.3.2.3.1 Loss of Specificity
            5.3.2.3.2 Low Specificity
            5.3.2.3.3 Low Sensitivity
    5.3.3 Neurology
       5.3.3.1 Application
       5.3.3.2 Drivers
            5.3.3.2.1 Relevant Information
            5.3.3.2.2 Efficient Diagnosis
            5.3.3.2.3 Assistant in Clinical Trials
       5.3.3.3 Restraints
            5.3.3.3.1 Complex Process
            5.3.3.3.2 Chromosomal Variation
            5.3.3.3.3 Hurdles in Tracking
       5.3.3.4 Alzheimer’s
       5.3.3.5 Multiple Sclerosis
       5.3.3.6 Parkinson's Disease
       5.3.3.7 Others (Renal Diseases, Urinal Disease)
 5.4 Drug Discovery and Development
    5.4.1 Application
    5.4.2 Drivers
       5.4.2.1 Increased Efficiency
       5.4.2.2 High Quality Support
       5.4.2.3 Cost Effective
       5.4.2.4 Collaboration for Novel Development
    5.4.3 Restraints
       5.4.3.1 Drug Metabolism
       5.4.3.2 Stability of Biomarkers
       5.4.3.3 Complex Process
 5.5 Drug Formulation
    5.5.1 Application
    5.5.2 Drivers
    5.5.3 Restraint
 5.6 Forensic Application
 5.7 Others (Dna Fingerprinting and Others)
    5.7.1 Blood Alcohol Concentration Biomarker
    5.7.2 Dna Fingerprinting

CHAPTER 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY SERVICES, 2013-2020, $MILLION
 6.1 Sample Preparation
    6.1.1 Application
       6.1.1.1 Biological Mass Spectrometry
    6.1.2 Drivers
       6.1.2.1 Cost Effective
       6.1.2.2 Sample Rigidity
       6.1.2.3 Efficient Forensic Studies
    6.1.3 Restraints
       6.1.3.1 Complex Structure
       6.1.3.2 Lack of Effectiveness
       6.1.3.3 Extensive Fractionation
       6.1.3.4 Loss of Biological Compounds
 6.2 Assay Development
    6.2.1 Application
       6.2.1.1 Clinical Trials
       6.2.1.2 Drug Development and Validation
       6.2.1.3 Others
    6.2.2 Drivers
       6.2.2.1 Accuracy
       6.2.2.2 Cost Effective
       6.2.2.3 imely Result
    6.2.3 Restraints
       6.2.3.1 Complexity in Technique
       6.2.3.2 Tissue Specific
 6.3 Biomarker Validation and Testing 
    6.3.1 Drivers
       6.3.1.1 Reduce Failure Rate
    6.3.2 Restraints
       6.3.2.1 Clinical Errors
       6.3.2.2 Time Consuming
 6.4 Other Services

CHAPTER 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY GEOGRAPHY, 2013-2020, $MILLION
 7.1 North America
 7.2 Europe
 7.3 Asia-Pacific
 7.4 Row (Rest of World)

CHAPTER 8 COMPETITIVE LANDSCAPE
 8.1 Product Launch
    8.1.1 Recent Development
 8.2 Collaboration and Partnership
    8.2.1 Recent Development
 8.3 Clearance and Approval
    8.3.1 Recent Development
 8.4 Mergers and Acquisition
    8.4.1 Recent Development

CHAPTER 9 COMPANY PROFILES
 9.1 Abbott Laboratories, Inc.
    9.1.1 Company Overview
    9.1.2 Company Snapshot
    9.1.3 Business Performance
    9.1.4 Strategic Moves and Developments
       9.1.4.1 Principal Strategies
       9.1.4.2 Secondary Strategies
    9.1.5 Swot Analysis & Strategic Conclusions
 9.2 Agilent Technologies Inc.
    9.2.1 Company Overview
    9.2.2 Company Snapshot
    9.2.3 Business Performance
    9.2.4 Strategic Moves and Developments
       9.2.4.1 Primary Strategies
       9.2.4.2 Secondary Strategies
    9.2.5 Swot Analysis & Strategic Conclusions
 9.3 Aushon Biosystem
    9.3.1 Company Profile
    9.3.2 Company Snapshot
    9.3.3 Strategic Moves and Developments
       9.3.3.1 Primary Strategies
       9.3.3.2 Secondary Strategies
    9.3.4 Swot Analysis & Strategic Conclusions
 9.4 Bio-Rad Laboratories
    9.4.1 Company Profile
    9.4.2 Company Snapshot
    9.4.3 Business Performance
    9.4.4 Strategic Moves and Developments
       9.4.4.1 Primary Strategies
       9.4.4.2 Secondary Strategies
    9.4.5 Swot Analysis & Strategic Conclusions
 9.5 Eisai Co. Ltd.
    9.5.1 Company Profile
    9.5.2 Company Snapshot
    9.5.3 Business Performance
    9.5.4 Strategic Moves and Developments
       9.5.4.1 Primary Strategies
       9.5.4.2 Secondary Strategies
    9.5.5 Swot Analysis & Strategic Conclusions
 9.6 Epistem Ltd.
    9.6.1 Company Profile
    9.6.2 Company Snapshot
    9.6.3 Business Performance
    9.6.4 Strategic Moves and Developments
       9.6.4.1 Primary Strategies
       9.6.4.2 Secondary Strategies
    9.6.5 Swot Analysis & Strategic Conclusions
 9.7 Ge Healthcare
    9.7.1 Company Profile
    9.7.2 Company Snapshot
    9.7.3 Business Performance
    9.7.4 Strategic Moves and Developments
       9.7.4.1 Principle Strategies
       9.7.4.2 Secondary Strategies
    9.7.5 Swot Analysis & Strategic Conclusions
 9.8 Roche Diagnostics Limited
    9.8.1 Company Profile
    9.8.2 Company Snapshot
    9.8.3 Business Performance
    9.8.4 Strategic Moves and Developments
       9.8.4.1 Principal Strategies
       9.8.4.2 Secondary Strategies
    9.8.5 Swot Analysis & Strategic Conclusions
 9.9 Siemens AG
    9.9.1 Company Profile
    9.9.2 Company Snapshot
    9.9.3 Business Performance
    9.9.4 Strategic Moves and Developments
       9.9.4.1 Primary Strategies
       9.9.4.2 Secondary Strategies
    9.9.5 Swot Analysis & Strategic Conclusions
 9.10 Thermo Fisher Scientific Inc.
     9.10.1 Company Profile
     9.10.2 Company Snapshot
     9.10.3 Business Performance
     9.10.4 Strategic Moves and Developments
         9.10.4.1 Primary Strategies
         9.10.4.2 Secondary Strategies
     9.10.5 Swot Analysis & Strategic Conclusions

LIST OF TABLES:

TABLE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY REVENUE 2011-2020 ($MILLION)
TABLE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY APPLICATION 2011-2020 ($MILLION)
TABLE 3 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR TECHNOLOGY 2011-2020 ($MILLION)
TABLE 4 DIAGNOSTIC BIOMARKER APPLICATION MARKET 2011-2020 ($MILLION)
TABLE 5 DIAGNOSTIC BIOMARKER APPLICATION MARKET 2011-2020 ($MILLION)
TABLE 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF IMAGING TECHNOLOGY 2011-2020 ($MILLION)
TABLE 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF BIOINFORMATICS 2011-2020 ($MILLION)
TABLE 8 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF PERSONALIZED MEDICINE 2011-2020 ($MILLION)
TABLE 9 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASES 2011-2020 ($MILLION)
TABLE 10 BIOMARKERS MARKET BY TYPES IN 2011-2020 ($MILLION)
TABLE 11 GLOBAL MARKET FOR BIOMARKERS OF EXPOSURE IN 2011-2020 ($MILLION)
TABLE 12 GLOBAL MARKET FOR BIOMARKERS OF EXPOSURE IN 2011-2020 ($MILLION)
TABLE 13 DIAGNOSTIC BIOMARKER APPLICATION MARKET IN 2011-2020 ($MILLION)
TABLE 14 GLOBAL DIAGNOSTIC BIOMARKER MARKET APPLICATION MARKET IN 2011-2020 ($MILLION)
TABLE 15 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF RISK ASSESSMENT IN 2011-2020 ($MILLION)
TABLE 16 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC IN 2011-2020 ($MILLION)
TABLE 17 DIAGNOSTIC BIOMARKER MARKET OF DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 18 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC IN 2011-2020 ($MILLION)
TABLE 19 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF CARDIOLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 20 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF CARDIOLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 21 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF NEUROLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 22 DIAGNOSTIC BIOMARKER MARKET FOR NEUROLOGY DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 23 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 24 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 25 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF DRUG FORMULATION IN 2011-2020 ($MILLION)
TABLE 26 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF FORENSIC APPLICATION IN 2011-2020 ($MILLION)
TABLE 27 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASES IN 2011-202 ($MILLION)
TABLE 28 DIAGNOSTIC BIOMARKER MARKET OF SERVICES IN 2011-202($MILLION)
TABLE 29 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF SERVICES IN 2011-2020 ($MILLION)
TABLE 30 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF SAMPLE PREPARATION IN 2011-2020 ($MILLION)
TABLE 31 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF ASSAY DEVELOPMENT IN 2011-2020 ($MILLION)
TABLE 32 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF BIOMARKER VALIDATION IN 2011-2020 ($MILLION)
TABLE 33 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER SERVICES IN 2011-2020 ($MILLION)
TABLE 34 GLOBAL DIAGNOSTIC BIOMARKER MARKET IN 2011-2020 ($MILLION)
TABLE 35 TYPES OF DEVELOPMENTS FROM 2013-2010
TABLE 36 RECENT DEVELOPMENT IN PRODUCT LAUNCH
TABLE 37 PRODUCT LAUNCHES FROM 2013-2010
TABLE 38 COLLABORATION AND PARTNERSHIP
TABLE 39 PARTNERSHIP AND COLLABORATION FROM 2013-2010
TABLE 40 RECENT DEVELOPMENT IN CLEARANCE AND APPROVAL
TABLE 41 DIAGNOSTIC BIOMARKER APPROVAL AND CLEARANCE FROM 2013-2010
TABLE 42 RECENT DEVELOPMENT IN MERGERS AND ACQUISITION
TABLE 43 MERGER AND ACQUISITION FROM 2013-2010
TABLE 44 ABBOTT LABORATORIES BUSINESS SNAPSHOT
TABLE 45 AGILENT TECHNOLOGIES INC. BUSINESS SNAPSHOT
TABLE 46 AUSHON BIOSYSTEM BUSINESS SNAPSHOT
TABLE 47 BIO-RAD LABORATORIES BUSINESS SNAPSHOT
TABLE 48 EISAI CO. LTD BUSINESS SNAPSHOT
TABLE 49 EPISTEM COMPANY BUSINESS SNAPSHOT
TABLE 50 GE HEALTHCARE BUSINESS SNAPSHOT
TABLE 51 ROCHE DIAGNOSTICS LIMITED BUSINESS SNAPSHOT
TABLE 52 SIEMENS INC. BUSINESS SNAPSHOT
TABLE 53 THERMO FISHER SCIENTIFIC INC. BUSINESS SNAPSHOT

LIST OF FIGURES:

FIG. 1 PATENTS APPLICATION FILLED BY GENERAL ELECTRICAL FOR IMAGING TECHNOLOGY IN INDIA (2012)
FIG. 2 SPIDER-CHART FOR CHANGES IN KEY ADVANTAGES FROM 2013-2020
FIG. 3 EXPECTED GROWTH OF BIOMARKERS APPLICATION FOR CANCER TESTING
FIG. 4 PATENT ANALYSIS BY GEOGRAPHY 2013
FIG. 5 TOP 10 KEY STRATEGIES SPIDER CHART 2012-2020
FIG. 6 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKER TECHNOLOGY
FIG. 7 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKERS IN APPLICATION
FIG. 8 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKERS IN SERVICES
FIG. 9 TOP 3 WINING STRATEGIES FROM 2012-2020
FIG. 10 TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 11 CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 12 LEADING CAUSES OF MORTALITY IN U.S. 2012
FIG. 13 COST ON ALZHEIMER`S DISEASE TO U.S. IN 2013 (IN BILLION)
FIG. 14 ESTIMATED DEATHS VS. ESTIMATED CASES IN DIFFERENT TYPES OF CANCER IN NORTH AMERICA 2013
FIG. 15 DEVELOPMENTAL STRATEGIES ADOPTED FROM 2013-2010
FIG. 16 DIAGNOSTIC BIOMARKER PRODUCT LAUNCH BY COMPANIES FROM 2013-2010
FIG. 17 PARTNERSHIP AND COLLABORATION OF COMPANIES FROM 2013-2010
FIG. 18 CLEARANCE AND APPROVAL OF TOP 5 COMPANIES FROM 2013-2010
FIG. 19 MERGERS AND ACQUISITION FROM 2013-2010
FIG. 20 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 21 ABBOTT LABORATORIES, INC.  FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 22 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 23 AGILENT TECHNOLOGIES INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 24 AGILENT TECHNOLOGIES INC. FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 25 SWOT ANALYSIS OF AGILENT TECHNOLOGIES
FIG. 26 SWOT ANALYSIS OF AUSHON BIOSYSTEM
FIG. 27 BIO-RAD LABORATORIES FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 28 BIO-RAD LABORATORIES FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 29 SWOT ANALYSIS OF BIO-RAD LABORATORIES
FIG. 30 EISAI CO. LTD FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 31 EISAI CO. LTD FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 32 SWOT ANALYSIS OF EISAI CO. LTD
FIG. 33 EPISTEM FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 34 EPISTEM FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 35 SWOT ANALYSIS OF EPISTEM
FIG. 36 GE HEALTHCARE FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 37 GE HEALTHCARE FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 38 SWOT ANALYSIS GE HEALTHCARE
FIG. 39 ROCHE DIAGNOSTICS LIMITED FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 40 ROCHE DIAGNOSTICS LIMITED FINANCIAL REVENUES (DIAGNOSTIC DIVISION) BY GEOGRAPHY (2012)
FIG. 41 SWOT ANALYSIS OF ROCHE DIAGNOSTICS LIMITED
FIG. 42 SIEMENS INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 43 SIEMENS INC. FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 44 SWOT ANALYSIS OF SIEMENS
FIG. 45 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 46 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY GEOGRAPHIC AREAS (2012)
FIG. 47 SWOT ANALYSIS OF THERMO FISHER SCIENTIFIC INC.

...
Publisher Name : Allied Market Research

SIMILAR MARKET STUDIES

Please Select Format
Single User :- US $ 4740
Five User:- US $ 5910
Enterprise User:- US $ 8250
Data Pack :- US $ 3840

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top